MARKET

BIOC

BIOC

Biocept
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.550
-0.020
-0.44%
Pre Market: 4.550 0 0.00% 08:12 05/06 EDT
OPEN
4.504
PREV CLOSE
4.570
HIGH
4.720
LOW
4.500
VOLUME
18
TURNOVER
--
52 WEEK HIGH
13.00
52 WEEK LOW
3.460
MARKET CAP
60.98M
P/E (TTM)
-2.6155
1D
5D
1M
3M
1Y
5Y
Cancer Biopsy Market Size, Share, Trends, Analysis and Forecast 2027
May 06, 2021 (Market Insight Reports) -- The Global Cancer Biopsy Market is estimated to value over USD 32.4 billion by 2027 end at a CAGR of over 6.1%...
Market Insight Reports · 5h ago
Biocept to Report First Quarter 2021 Financial Results and Host Investor Conference Call on May 12, 2021
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will release financial results for the three months ended March 31, 2021 after the market closes on Wednesday, May 12, 2021. The Compa...
BusinessWire · 1d ago
Liquid Biopsy Market to Register Incremental Revenue Opportunities During the Forecast Period 2021-2027
May 05, 2021 (Heraldkeepers) -- Market Research Engine has published a new report titled as "Liquid Biopsy Market Size By Application (Non-Cancer...
Heraldkeepers · 1d ago
Global Circulating Tumor Cells Market Report 2021-2028: Kits & Reagents, Blood Collection Tubes, Devices & Systems
Dublin, May 05, May 05, 2021 (GLOBE NEWSWIRE via COMTEX) -- Dublin, May 05, 2021 (GLOBE NEWSWIRE) -- The "Circulating Tumor Cells Market Share, Size, Trends,...
GlobeNewswire · 1d ago
Clinical Trial Management (CTM) Market 2021 CAGR Status, Analysis, Latest Trends, Share, Industry Size, Revenue with Covid-19 Impact till 2026
May 05, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry.” Global “Clinical Trial Management (CTM)...
The Express Wire · 1d ago
Circulating Tumor Cell Diagnostics Market Research Report: Size, Share, Opportunities, Challenges, Statistics, Restraints, Drivers with Key Player by 2021-2027
May 04, 2021 (Heraldkeepers) -- Global circulating tumor cell diagnostics market is segmented based on the technology as, CTC Enrichment Methods, CTC...
Heraldkeepers · 1d ago
Global Clinical Trial Management (CTM) Market Size 2021 Analysis By Current Industry Status, Top Key Players, Growth Opportunities, Industry Trends Under COVID-19, Target Audience and Forecast To 2025
May 03, 2021 (The Expresswire) -- Global “Clinical Trial Management (CTM) Market" Research Report 2021-2025: This report elaborates the market size, market...
The Express Wire · 3d ago
Global Molecular Diagnostics for Cancer Markets Report 2021-2025: Market is Positioned to Directly Benefit from the Explosion in Genomics but Shifting Resources to COVID May Interrupt Growth
Dublin, April 30, Apr 30, 2021 (GLOBE NEWSWIRE via COMTEX) -- Dublin, April 30, 2021 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics for Cancer 2021-2025:...
GlobeNewswire · 6d ago
More
Forecast
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BIOC. Analyze the recent business situations of Biocept through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BIOC stock price target is 12.00 with a high estimate of 12.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 40
Institutional Holdings: 1.28M
% Owned: 9.57%
Shares Outstanding: 13.40M
TypeInstitutionsShares
Increased
4
62.43K
New
9
222.42K
Decreased
5
84.53K
Sold Out
4
13.97K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.94%
Healthcare Equipment & Supplies
-0.58%
Key Executives
Non-Executive Chairman
David Hale
President/Chief Executive Officer/Director
Michael Nall
Chief Financial Officer/Senior Vice President/Secretary
Timothy Kennedy
Senior Vice President
Michael Dugan
Senior Vice President
Michael Terry
Chief Compliance Officer/General Counsel
Michael Brown
Vice President/Director of Sales
Scott Nicholson
Vice President/Director of Sales
Antonio Paternostro
Director of Marketing
Brenda Tang
Other
Deirdre Goehler
Other
Gary Marchetti
Other
Tom Nauman
Other
Tim Schofield
Director
Samuel Riccitelli
Independent Director
Marsha Chandler
Independent Director
Bruce Gerhardt
Independent Director
Ivor Royston
Independent Director
Margaret Faye Wilson
No Data
About BIOC
Biocept, Inc. is a molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.

Webull offers kinds of Biocept Inc stock information, including NASDAQ:BIOC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIOC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BIOC stock methods without spending real money on the virtual paper trading platform.